TuHURA Biosciences (NASDAQ:HURA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA) from a sell rating to a hold rating in a report released on Saturday morning.

Separately, Brookline Capital Management raised TuHURA Biosciences to a “strong-buy” rating in a report on Monday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat.com, TuHURA Biosciences has a consensus rating of “Buy” and an average target price of $12.67.

TuHURA Biosciences Price Performance

Shares of HURA stock opened at $2.55 on Friday. The business has a 50-day simple moving average of $2.68 and a 200-day simple moving average of $3.03. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $8.40.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07).

Institutional Investors Weigh In On TuHURA Biosciences

Several large investors have recently bought and sold shares of the company. Suncoast Equity Management grew its position in shares of TuHURA Biosciences by 4.4% in the second quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock valued at $233,000 after purchasing an additional 4,412 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of TuHURA Biosciences in the second quarter valued at approximately $27,000. Intech Investment Management LLC purchased a new stake in shares of TuHURA Biosciences in the second quarter valued at approximately $29,000. Jefferies Financial Group Inc. purchased a new stake in shares of TuHURA Biosciences in the fourth quarter valued at approximately $54,000. Finally, Invesco Ltd. purchased a new stake in shares of TuHURA Biosciences in the second quarter valued at approximately $30,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.